Utah Governor Spencer Cox joined Kelvyn Cullimore, President and CEO of BioUtah, to recognize Co-Diagnostics, Inc. (Nasdaq: CODX) for its recent announcement of a joint venture (JV) in the Kingdom of Saudi Arabia. The JV, named CoMira Diagnostics, marks a significant expansion for the Utah-based molecular diagnostics company into the Middle East and North Africa region.
Governor Cox praised the company's global reach, stating, "Co-Diagnostics is a Utah-born company competing on the world stage. Their expansion across the Middle East and North Africa reflects the strength of Utah’s life sciences and the grit of our entrepreneurs. We’re proud to see a Utah company building tools that help more patients around the world."
Kelvyn Cullimore of BioUtah echoed the sentiment, noting that the definitive JV agreement "further confirms Co-Diagnostics’ expanding leadership and presence on the worldwide stage." He added, "We couldn’t be more pleased with the way they represent the Utah life sciences community, one of the fastest growing in the United States."
Co-Diagnostics, a member of BioUtah's Elite tier, develops, manufactures, and markets advanced molecular diagnostic tests using its patented platform. The company also designs tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and identifies genetic markers for applications beyond infectious disease.
The recognition follows Co-Diagnostics' recent announcement of the JV, which aims to strengthen the company's footprint in the Middle East and North Africa. This expansion aligns with Utah's broader life sciences growth, which has been recognized as one of the fastest-growing sectors in the United States.
BioUtah, an independent trade association serving Utah's life sciences industry, represents companies involved in medical device manufacturing, research and testing, biotechnology, biopharmaceuticals, and diagnostics. The organization highlighted Co-Diagnostics as a key example of Utah's innovative and globally competitive life sciences community.
